AIM
NMTR

Axiom Investment Management’s 9 Meters Biopharma NMTR Stock Holding History

Axiom Investment Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4
Closed – – 464
2022
Q3 		$0 Buy
+4
New +$20 ﹤0.01% 475

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Axiom Investment Management's NMTR Position: Q4 2022 in Review

Axiom Investment Management sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 4 shares.

Axiom Investment Management first reported a position in NMTR in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

  • Axiom Investment Management reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
  • Axiom Investment Management sold 4 9 Meters Biopharma shares in Q4 2022.
  • Axiom Investment Management first reported a position in 9 Meters Biopharma in Q3 2022 and held it in 1 quarter.
  • Axiom Investment Management's 9 Meters Biopharma position peaked at $0 in Q3 2022.
  • 42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Axiom Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.